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Refractory acute graft-versus-host disease (aGVHD) remains an important cause of mortality after allogeneic
stem cell transplantation. No standard therapy exists once steroids fail to obtain a good response. In 2006, our
group published a series of patients who received inolimomab, an antieinterleukin-2 receptor monoclonal
antibody, as salvage therapy with initial encouraging results. In this update, we analyzed a larger group of
patients with prolonged follow-up. Ninety-two consecutive patients were treated with inolimomab at our
center between April 1999 and December 2011. Overall response rate was 42% (complete response in 14%) on
day þ30. Predictors of failure to respond in the multivariate analysis were overall aGVHD grade IV, instau-
ration of inolimomab before day 15 of aGVHD diagnosis, and severe lymphopenia. Patients without gastro-
intestinal involvement appeared to do better, with a 70% response rate compared with 39% in patients with
gastrointestinal involvement (P ¼ .06). However, the 2-year overall survival rate was of 18% for the entire
cohort (95% conﬁdence interval, 10% to 26%) and 33% for day 30 responders (95% conﬁdence interval, 25% to
40%) and Acute GVHD was the main cause of death (49%) followed by opportunistic infections (27%). Results
of this update show that although inolimomab is a well-tolerated drug with a moderate number of short-
term responses, it is associated with long-term survival in only one-third of responding patients. These
data highlight the need to investigate new rescue treatments with sustained effect and the importance of
reporting long-term outcomes in GVHD studies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION New, recently published recommendations [7-9] call for
Acute graft-versus-host disease (aGVHD) is the most
important cause of non-relapse mortality after allogeneic
stem cell transplantation. Its incidence varies between 30%
and 80% depending on various risk factors (eg, recipient age,
gender disparity, cytomegalovirus serostatus, disease status,
stem cell source, human leukocyte antigen mismatch, etc.),
and its initial therapy consists of systemic corticosteroids (2
mg/kg daily prednisone or equivalent dose of other steroids)
[1-3]. Refractoriness to steroids, which occurs in approxi-
mately 50% of patients, is associated with a poor prognosis
(approximately 5% to 30% of long-term survivors) [3].
Although multiple second-line therapies (antithymocyte
globulin, mycophenolate mofetil, sirolimus, photopheresis,
etc.) have been used, often with initial encouraging results,
none has been established as a good option, and there is no
deﬁned standard salvage therapy [3,4]. The development of
new strategies for effective intervention before the develop-
ment of steroid-refractory disease is also under study. A
multicenter, randomized, double-blind, phase III trial evalu-
ating the addition ofmycophenolatemofetil versus placebo in
addition to systemic corticosteroids as initial therapy for
aGVHDwas closed early for accrual in November 2011 due to
lack of beneﬁt [5,6].edgments on page 439.
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studies. Clear deﬁnition of inclusion and response criteria
(avoiding best response as endpoint), 28-day evaluation of
efﬁcacy, considering as failure the use of other salvage treat-
ment(s), and including at least a 6-monthoverall survival (OS)
rate are some of the most important recommendations.
New advances in the understanding of aGVHD immune
pathophysiology emphasize the important role that inﬂam-
matory interleukins have in the activation and proliferation
of effector T cells, making them an interesting target for
monoclonal antibodies [10-12]. In June 1999, we began to use
inolimomab, a monoclonal antibody directed against the
interleukin-2 receptor, for refractory aGVHD, and since 2006
this has been our standard salvage therapy for steroid-
refractory aGVHD [13], based on preliminary encouraging
results (58% overall responses, 38% complete responses
[CRs], and 59% 1-year survival in responding patients).
In this article, we update our results in a larger group of
patients with prolonged follow-up. We made an effort to
improve the quality of the study by following the recent
recommendations [7] considered important in reporting
aGVHD studies.METHODS
This single-center, retrospective study analyzed the outcomes of 92
consecutive adult patients who received inolimomab as salvage treatment
for steroid-refractory aGVHD between April 1999 and December 2011. The
sole treatment criterion was presence of steroid-refractory grades II to IV
aGVHD, including both classical and late-onset forms. Three patients diag-
nosed with an overlap syndrome who presented predominantly aGVHDTransplantation.
Table 1
Patient Characteristics
Characteristics Value n (%)
Median age, yr (range) 50 (17-68)
Gender male 65 (71)
Sex mismatch: female donor to male recipient 25 (27)
Underlying disease
Acute leukemia 29 (32)
MDS and MPS 29 (32)
Chronic lymphoproliferative diseases 25 (27)
Others 9 (10)
Advanced disease status at HSCT 59 (64)
Recipient and donor CMV negative 7 (8)
Stem cell source
Peripheral blood 77 (84)
Bone marrow 10 (11)
Cord blood 5 (5.4)
Donor type
HLA identical sibling 52 (56)
Alternative 40 (44)
EBMT risk index
Low risk (score 0-1) 9 (10)
Intermediate risk (score 2-3) 38 (41)
High (score 4-6) 45 (49)
Conditioning regimen
Reduced intensity (ﬂudarabine plus melphalan
or busulphan)
65 (71)
High-dose myeloablative 28 (30)
Alemtuzumab or ATG pretransplantation 16 (17)
GVHD prophylaxis
CsA-based immunosupression 85 (92)
Tacrolimus plus sirolimus 7 (8)
Inolimomab as ﬁrst-line salvage therapy 46 (50)
NR to prior salvage therapies 46 (50)
MMF 22 (24)
ATG 20 (22)
CsA 3 (3)
Median time from allo-SCT to aGVHD onset,
d (range)
34 (5-170)
Median time from onset of aGVHD to start of
inolimomab, d (range)
16 (2-204)
Overall aGVHD grade at start of inolimomab
II 6 (6.5)
III 48 (52)
IV 38 (41)
Organs involved by aGVHD at the start of
inolimomab
GI tract 82 (90)
Liver 64 (70)
Skin 79 (86)
Platelets at the start of inolimomab, 109/L,
median (range)
40 (2-264)
Lymphocyte count at the start of
inolimomab, 109/L, median (range)
0.33 (0-2.5)
Albumin at the start of inolimomab, g/L,
median (range)
26 (13-42)
MDS indicates myelodysplastic syndrome; MPS, myeloproliferative syn-
drome; HSCT, hematopoietic stem cell transplantation; CMV, cytomegalo-
virus; EBMT, European Group for Blood and Marrow Transplantation; CsA,
cyclosporine A; MMF, mycophenolate mofetil; ATG, antithymocyte globulin.
Advanceddisease statuswas considered inpatientswithacute leukaemia in at
least second CR, myeloproliferative disease in at least second chronic phase,
accelerate or blast phase, Hodgkin disease in at least third complete remission
or with PR, follicular lymphoma in at least third CR, large B cell lymphoma or
multiplemyeloma in at least second CR or PR, and solid tumors. Patients with
persistent disease at transplantation (except for myeloma) were also
considered as advanced disease status.
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ical ﬁndings and conﬁrmed with histological evaluation of affected organ(s).
Overall grading followed the Przepiorka standard criteria [14]. Failure of
corticosteroids was deﬁned by overall aGVHD grade progression within 3
days of treatment or absence of response by day 5. No patients were
excluded because of active infection, progressive disease, poor performance
status, or any other cause. All patients gave their informed consent, and the
drug was administered as compassionate use after approval by our insti-
tutional and national health authorities. During the study, 3 patients wereconsidered for a clinical trial using mesenchymal cells after failure of ino-
limomab therapy and thus were not excluded from the analysis.
Inolimomab was administered intravenously at a dose of 11 mg/d for
3 days, 5.5 mg/d for 7 days, and 5.5 mg every other day for 5 doses (21 days
per course). Sixty-ﬁve patients (71%) received 1 course of inolimomab,
25 patients (27%) received 2 courses, and 2 patients received 3 courses due
to absence of response or relapse after responding to a ﬁrst course of the
drug. In addition to steroids, other prior immunosuppressors were not
discontinued at the start of inolimomab, with the exception of patients who
were on antithymocyte globulin.
Staging of target organs and the overall grade of aGVHD was done in
detail at baseline and on days þ7, þ15, þ30, and þ60 of the start of inoli-
momab. CR was deﬁned as the sustained disappearance of all GVHD clinical
and laboratory features, whereas partial response (PR) was an overall
improvement of at least 1 grade without progression in any organ. The
overall response rate (ORR) includes CR plus PR rates. Those patients who
showed improvement in 1 organ but progressed in another were considered
to have progression of aGVHD. No response included stable, progressive
aGVHD and patients who started another drug as salvage therapy.
Recent studies [8,9] have shown that the day 28 response is the
strongest predictor of non-relapsemortality (NRM) after starting therapy for
aGVHD. For this reason, we selected “dayþ30 response” as the primary early
endpoint (detailed in Statistical Analysis, below). All patients received the
treatment as inpatients in HEPA-ﬁltered-air rooms. Supportive measures
were considered of primary importance in these patients and included in all
instances antiviral, antifungal, and cotrimoxazole prophylaxis. Serial blood
monitoring of galactomanan, cytomegalovirus infection, and Epstein-Barr
virus infection was done 1-3 times a week, as described elsewhere [15].
Statistical Analysis
Cross-tabs and the Student’s t test were used to identify baseline char-
acteristics associated with the day þ30 response to inolimomab. Response
and survival endpoints were calculated using the starting date of inolimo-
mab therapy. Factors associated with ORR on day þ30 in univariate analysis
(P < .10) were then entered into a multivariate Cox regression analysis.
P values <.05 were considered statistically signiﬁcant, and hazard ratios
and 95% conﬁdence intervals (CIs) were calculated. Survival was estimated
by the Kaplan-Meier method, and comparisons of actuarial curves were
made with the log-rank test. Finally, to evaluate the impact of the day þ30
response on survival, we performed a landmark analysis including only
those patients who were alive on day þ30 (n ¼ 58).
RESULTS
Patients and GVHD Characteristics
Characteristics of the 92 patients treated are detailed in
Table 1. All patients were diagnosed with hematological
malignancies, and 90% had an intermediate or high European
Group for Blood andMarrowTransplantation risk score before
allogeneic stem cell transplantation. Donors were human
leukocyte antigeneidentical siblings in 52 cases (57%).
Several GVHD prophylaxis regimenswere used and, in 78%
of cases, were cyclosporine-based combinations (plus meth-
otrexate ormycophenolatemofetil). Themedian follow-up for
survivors was 60 months (range, 6-145). aGVHD occurred at
a median of 34 days after transplantation (range, 5-170 days),
and 94% of patients developed grade III or IV aGVHD. Involved
organs were the gastrointestinal (GI) tract in 82 cases (90%),
the liver in 64 (70%), and the skin in 79 (86%). Inolimomabwas
initiated at a median of 17 days (range, 2-204 days) after the
onset of aGVHD. Forty-six patients (50%) received inolimomab
as ﬁrst-line salvage therapy, whereas another 46 patients
received this treatment after failure of prior therapy for
steroid-refractory aGVHD (see Table 1 for details).
Toxicity and Infections
Inolimomab was well tolerated, without infusion-related
reactions. Two patients developed probable drug-related
side effects. One of them developed a rapid increase of
liver transaminases (without prior hepatic GVHD or use of
parenteral nutrition), and inolimomab was discontinued
after 10 days of therapy. The other patient developed a mild
cutaneous rash that required only symptomatic therapy.
Table 2
Univariate andMultivariate Risk Factor Analysis for Response to Inolimomab
Therapy by Day þ30 after Start of Therapy
Predictors of Day þ30 Response
Variable CR or PR to Salvage Inolimomab
Therapy
Univariate
Analysis
Multivariate
Analysis
Day 30
Response (%)
P HR, 95% CI P
EBMT risk index
Low and intermediate
risk (score 0-3)
51 .09 NA .2
High (score 4-6) 33
Overall aGVHD grade at
inolimomab onset
II-III 52 .03 HR 1.8, 95%
CI 1.06-3
.03
IV 29
Line of salvage therapy for
refractory aGVHD
NT
First or second 30 .161
Third or higher 23
Courses of inolimomab NT
One course, 65 (71%) 28 NS
More than 1 course, 27
(29%)
25
Lymphocyte count at the
start of inolimomab
>.3  109/L 51 .089 HR 1.9, 95%
CI 1.1-3.3
.02
.3  109/L 32
Stage of GI aGVHD at
inolimomab onset
Stage 0-II 52 .09 NA .08
Stage III-IV 33
Serum albumin at start of
therapy
NT
 30g/L 49 NS
<30 g/L 34
CMV serostatus NT
Donor and receptor
negative
Donor and/or receptor
seropositive
42
43
NS
HLA matching
Mismatch HLA 40 NS NT
No mismatch 52
Onset of inolimomab
After day 15 54 .021 HR 1.9, 95%
CI 1.1-3.4
.01
Before day 15 29
Year of treatment NT
Before 2005 49 NS
After 2005 37
HR indicates hazard ratio; EBMT, European Group for Blood and Marrow
Transplantation; NA, not available; NT, not tested; NS, not signiﬁcant; GI,
gastrointestinal; CMV, cytomegalovirus; HLA, human leukocyte antigen.
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available for 84 patients (91.3%). Seventy-two developed at
least 1 infectious episode during the follow-up period.
Cytomegalovirus reactivation was detected in 49 patients
(15 with cytomegalovirus disease) at a median time of 7 days
(range,þ1 -þ103 days) from the start of the therapy. Twenty
patients (22%) developed an invasive fungal infection
(14 cases of invasive aspergillosis and 4 cases of candidemia).
Fifty-three patients developed at least 1 bacterial infection,
being staphylococcal bacteremia the most common of these
infections (n ¼ 26 patients).
Response
The ORR on days þ15, þ30, and þ60 of therapy was 36%
(CR 2%), 42% (CR 14%), and 46% (CR 26%), respectively.
Patients who received inolimomab as ﬁrst-line salvage
therapy presented an ORR of 39% (CR 0%), 39% (CR 13%), and
50% (CR 26%) on days þ15, þ30 and þ60, respectively,
days þ15, þ30, and þ60. Patients without GI involvement
(n ¼ 10) responded better, with a 70% response rate com-
pared with a 39% response rate in patients with GI involve-
ment (n ¼ 82; P ¼ .06).
Predictors of day þ30 response are shown in Table 2. In
multivariate analysis, grades II to III overall aGVHD (hazard
ratio, 1.8; 95% CI, 1.1 to 3.2; P ¼ .03), no severe lymphocy-
topenia (hazard ratio, 1.9; 95% CI, 1.1-3.3; P ¼ .02), and onset
of inolimomab later than 15 days after aGVHD diagnosis
(hazard ratio, 1.9; 95% CI, 1.1-3.4; P ¼ .01) were signiﬁcantly
associated with response on day þ30.
Two of the 3 patients diagnosed with an overlap syn-
drome were in PR on day 30 and achieved CR by day 60 after
inolimomab. One patient is still alive in CR, whereas the
other died from progression of Hodgkin’s lymphoma. The
third patient did not respond to inolimomab and died due to
GVHD.
Survival
OS at 6,12, and 24monthswas 34% (95% CI, 24%-44%), 22%
(95% CI, 13%-31%), and 18% (95% CI, 10%-26%), respectively
(Figure 1). GVHD was the main cause of death, either aGVHD
(49%) or chronic GVHD (13%), followed by opportunistic
infections (27%). On the other hand, relapse of the underlying
disease was the cause of death in only 4% of patients, even
among the 42% who responded to inolimomab on day þ30
(2 of 39 responders [5%] died from relapse). To analyze the
impact of responding to inolimomab on survival, we per-
formed a landmark analysis on dayþ30 of therapy, including
only the 58 patients alive at this time (39 responders and 19
nonresponders). The OS at 6 months and 2 years was higher
in responders: 6-month OS 67% (95% CI, 52%-82%) versus 26%
(95% CI, 6%-46%) and 2-year OS 33% (95% CI, 18%-48%) versus
20% (95% CI, 1%-40%) (P ¼ .03), respectively (Figure 1).
Multivariate analysis was not done because of the small
patient numbers.
DISCUSSION
In this current single-center study, the use of inolimomab
as salvage therapy for steroid-refractory aGVHD was associ-
ated with prolonged survival in only 18% of patients and in
approximately one-third of day þ30 responding patients.
The updated results conﬁrm that inolimomab may be an
active drug in this setting, with an ORR of 42%-48% on
days þ30 to þ60 of therapy. However, the poor long-term
outcomes highlight the importance of reporting long-term
results in studies of steroid-refractory aGVHD [7].Variables found to improve the dayþ30 ORR were mostly
expected (aGVHD <grade IV, no severe lymphocytopenia,
and a trend for nonsevere GI involvement). The improved
outcome in patients who started inolimomab therapy more
than 15 days after aGVHD onset probably reﬂects a time-
dependent selection bias; patients who survive longer after
aGVHD onset and under high-dose steroids may be biologi-
cally more ﬁt and/or have a slower-progressing (or less-
aggressive) aGVHD. Supportive care has dramatically
improved over the past 2 decades, and this surely contributes
to the improved short-term outcome in patients who
respond to salvage GVHD treatment. However, the outcome
of patients with refractory GVHD has not improved over
time, and because this was the cause of death in 62% of
Figure 1. Two-year overall survival (A) for the whole population and (B) for
day þ30 responders and nonresponders.
Table 3
Martin Criteria Applied in Our Study
Criteria Met Explanation
1. Adequately deﬁned
eligibility criteria
Yes Inclusion/exclusion criteria are
deﬁned in Methods. They were
maintained unchanged along the
time.
2. Minimization of bias
in patient selection
No A possible selection bias cannot
be excluded because of the
retrospective nature of our
analysis. If any, the bias should
affect negatively the results, as
only those patients affected with
refractory mild aGVHD and
isolated skin involvement who
responded to oral second-line
therapy (as MMF or sirolimus)
could be lost. Probably the
included patients represent the
most severe cases, which are the
main problem in the clinical
setting.
3. Consistent treatment
regimen
Yes All the patients received the same
dose, schedule, and duration of
inolimomab. Description of
concomitant treatment (with the
exception of corticosteroids
previous days and dosage) is
provided and was considered in
the response and survival analysis.
4. Objective criteria for
organ response
Yes Objective criteria were used
(described in Methods).
5. Unambiguous criteria
for overall response
Yes Stringent criteria were used for
overall response, consisting of a
global reduction of at least 1
grade in the overall evaluation
without impairment in any organ.
Patients with improvement in 1
organ but deterioration in another
were classiﬁed as progression
(detailed in Methods).
6. Prespeciﬁed time for
response assessment
Yes Response was reevaluated every
week. Following the new
recommendations, we analyzed
the response by day þ30. Deaths,
relapses, and introduction of other
therapies were considered and
included as competitive events in
the analysis.
7. Concomitant treatment
taken into account
Yes Use of new immunosuppressants
after the enrollment was
considered as treatment failure.
8. Well-established
control benchmark
No No control could be used.
Historical cohort of patients who
received other second-line agents
cannot be used because support
therapy deeply changed in the last
10 years.
9. Statistical hypothesis
and power estimate
NA Not applicable due to the
retrospective nature of the study.
10. Survival Yes Survival at 6 months and 1 and
2 years from the onset of the study
is shown.
MMF indicates mycophenolate mofetil; NA, not applicable.
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possible beneﬁt of improved supportive care.
Treatment with inolimomab was well tolerated, as
previously reported [10], and the infection-related mortality
(27%) was not as high as that observed with other drugs, such
as antithymocyte globulin [16]. Of course, it is not possible to
attribute severe infections solely to inolimomab, because
these much-debilitated patients receive other immunosup-
pressive agents that contribute to opportunistic infections.
Despite the retrospective nature of the current study, a
strong effortwas put forth tomeet the quality criteria recently
considered important in reporting the results of secondary
treatment for steroid-refractory aGVHD. In addition, the study
was based ona consecutive series of patientswho received the
same therapywithoutmajor changes over time. Table 3 shows
the compliance of our study with the 10 quality criteria
recently considered important in these studies [7].
The main strengths of our report are as follows: (1) clear
deﬁnition of inclusion criteria, (2) no exclusion of patients
with an Eastern Cooperative Oncology Group performance
status >2 or active infection, (3) no changes in inolimomab
posology over time, (4) response evaluation at established
time points (especially day þ30 in our study, due to the
predictive value of day þ28 response [8,9]) with predeﬁned
criteria, (5) exclusion of patients who died before the day of
evaluation in the statistical analysis, and (6) estimation of
long-term survival.
A limitation of the study is the absence of a control group.
In an effort to mitigate this problem, we compared ourresults with those compiled in the recent extensive review
byMartin et al. [7]. Due to the heterogeneity of patients with
steroid-refractory aGVHD, a direct comparison of the
outcomes reported herein with other studies cannot be
made. Nevertheless, inolimomab does not appear to offer any
advantage over other reported treatment options. The CR/PR
in our study was 42% and 46% on day þ30 and þ60,
respectively, which is similar to the 43% ORR described in
a prior phase II study with an antieinterleukin-2 receptor
monoclonal antibody [17]. In comparison, the median ORR in
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addition, the CR rate found in the current study compares
poorly with the 32% median CR rate observed in prior
studies, with a 95% CI of 20%-40%, and thus our 14% CR rate is
lower than the estimated 95% CI of prior pooled studies. The
same is applicable to the 6-month OS rate; in the review by
Martin et al. [7], the median 6-month OS rate was 49% (95%
CI, 40%-60%). Again, our observed 6-month OS rate of 34%
(95% CI, 24%-44%) also seems statistically poorer than those
observed with other drugs. Of course, our “worse-than-ex-
pected” outcomes are surely inﬂuenced by the real-life
clinical use of inolimomab in the current study, thus
including very sick patients who would have been excluded
from prospective trials or observational studies [5,6].
In conclusion, although inolimomab is a well-tolerated
drug in patients with refractory aGVHD, its activity does
not seem better than reported with other drugs. More
important, long-term survival in this large series of patients
appears to be very low. Whether results can be improved
with currently available treatments is uncertain, and efforts
should be directed in participating in clinical trials testing
novel therapeutic approaches.
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